Novartis received approval from the Food and Drug Administration to produce its Pluvicto radioligand therapy at its new manufacturing facility in Indianapolis, expanding capacity to meet growing demand for cancer patients in North America.
The Swiss pharmaceutical company said Friday that the decision from the FDA would lift radioligand therapy production capacity to 250,000 doses in 2024 and beyond.
[
add
]
[
|
|
...
]